Market Spotlight: Hepatitis B
Market Spotlight: Hepatitis B
$1,318.00
This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- It is estimated that in 2019, there were approximately 297.0 million prevalent cases of hepatitis B worldwide, with only 9.9% (29.4 million) of those cases estimated to be diagnosed.
- In the same year, there were an estimated 4.9 million prevalent cases that were treated with an antiviral. Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, interferon receptor, interferon-alpha, and the immune system. The majority of these drugs are administered via the oral route, with the remainder being intramuscular, subcutaneous, intravenous, intradermal, and topical formulations.
- The majority of industry-sponsored drugs in active clinical development for hepatitis B are in Phase II, with no drugs in Phase III. Therapies in development for hepatitis B focus on a wide variety of targets. The largest number of pipeline drugs in development are administered orally, with the remainder being intravenous, intramuscular, and subcutaneous formulations.
- High-impact upcoming events for drugs in the hepatitis B space comprise topline Phase II trial results for EYP001, RG7854, RG7907, and ALN-HBV02.
- The overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a drug advances from Phase III is 68.3%. Drugs, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
- There have been equal proportions of clinical trials for hepatitis B across phases of development, with 50% in Phase I–II, and 50% in Phase III–IV.
- China leads in terms of the number of hepatitis B clinical trials globally, while Germany leads the major European markets. Clinical trial activity in the hepatitis B space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for hepatitis B, with 319 trials.
- GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for hepatitis B, followed by Gilead.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 TREATMENT
10 Nucleos(t)ide analogs
10 Interferons
11 EPIDEMIOLOGY
18 MARKETED DRUGS
21 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Vebicorvir for Hepatitis B (November 5, 2020)
29 AB-729 for Hepatitis B (May 18, 2020)
31 Inarigivir for Hepatitis B (January 29, 2020)
32 Inarigivir for Hepatitis B (December 26, 2019)
33 Vebicorvir for Hepatitis B (November 11, 2019)
34 IONIS-HBVRx for Hepatitis B (November 11, 2019)
36 GSK3389404 for Hepatitis B (November 8, 2019)
38 JNJ-3989 for Hepatitis B (November 8, 2019)
39 JNJ-6379 for Hepatitis B (November 8, 2019)
41 HLX10 for Hepatitis B (September 12, 2019)
42 KEY UPCOMING EVENTS
43 PROBABILITY OF SUCCESS
44 LICENSING AND ASSET ACQUISITION DEALS
44 Gilead Collaborates With Vir On HBV Cure
44 Assembly, Door Join Forces In Hepatitis B
44 Aligos Deals Separately Target COVID-19, Hepatitis B
44 BeiGene Acquires Rights To Three Assembly HBV Candidates
46 REVENUE OPPORTUNITY
48 CLINICAL TRIAL LANDSCAPE
49 Sponsors by status
50 Sponsors by phase
51 Recent events
53 BIBLIOGRAPHY
53 Prescription information
54 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of hepatitis B, 2019–28
21 Figure 2: Overview of pipeline drugs for hepatitis B in the US
21 Figure 3: Pipeline drugs for hepatitis B, by company
22 Figure 4: Pipeline drugs for hepatitis B, by drug type
22 Figure 5: Pipeline drugs for hepatitis B, by classification
29 Figure 6: Vebicorvir for Hepatitis B (November 5, 2020): Phase II – Study 211
31 Figure 7: AB-729 for Hepatitis B (May 18, 2020): Phase Ia/Ib – AB-729-001
36 Figure 8: IONIS-HBVRx for Hepatitis B (November 11, 2019): Phase II – Chronic HBV (CS3)
38 Figure 9: GSK3389404 for Hepatitis B (November 8, 2019): Phase II – SAD/MAD (Chronic HBV)
42 Figure 10: Key upcoming events in hepatitis B
43 Figure 11: Probability of success in the antiviral pipeline
48 Figure 12: Clinical trials in hepatitis B
48 Figure 13: Top 10 drugs for clinical trials in hepatitis B
49 Figure 14: Top 10 companies for clinical trials in hepatitis B
49 Figure 15: Trial locations in hepatitis B
50 Figure 16: Hepatitis B trials status
51 Figure 17: Hepatitis B trials sponsors, by phase
LIST OF TABLES
12 Table 1: Global prevalent cases of hepatitis B, 2019–28
14 Table 2: Diagnosed prevalent cases of hepatitis B, 2019
16 Table 3: Treatment-eligible and treated prevalent cases of hepatitis B, 2019
19 Table 4: Marketed drugs for hepatitis B
23 Table 5: Pipeline drugs for hepatitis B in the US
28 Table 6: Vebicorvir for Hepatitis B (November 5, 2020)
30 Table 7: AB-729 for Hepatitis B (May 18, 2020)
31 Table 8: Inarigivir for Hepatitis B (January 29, 2020)
32 Table 9: Inarigivir for Hepatitis B (December 26, 2019)
33 Table 10: Vebicorvir for Hepatitis B (November 11, 2019)
35 Table 11: IONIS-HBVRx for Hepatitis B (November 11, 2019)
37 Table 12: GSK3389404 for Hepatitis B (November 8, 2019)
38 Table 13: JNJ-3989 for Hepatitis B (November 8, 2019)
40 Table 14: JNJ-6379 for Hepatitis B (November 8, 2019)
41 Table 15: HLX10 for Hepatitis B (September 12, 2019)
46 Table 16: Historical global sales, by drug ($m), 2015–19
47 Table 17: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Hidradenitis Suppurativa 
Sign up to the